RQ Biotechnology

RQ Bio is a private, preclinical-stage biotechnology company developing a novel class of long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza. The company aims to address the significant unmet need in immunocompromised populations—such as newborns, the elderly, and patients with chronic conditions—who are at high risk of severe disease and often exhibit suboptimal responses to seasonal flu vaccines. By engineering antibodies for immediate and durable protection, RQ Bio seeks to mitigate the annual global threat posed by influenza's seasonal evolution, which undermines vaccine effectiveness. The company is headquartered in London and appears to be in a venture-backed, pre-revenue stage of development.

Discovery and engineering of long-acting monoclonal antibodies (LAAbs) for passive immunization, focusing on extended half-life and potent neutralization against viral targets.

The competitive landscape includes major vaccine manufacturers (Sanofi, GSK, Seqirus) producing seasonal flu vaccines, and companies developing next-generation universal flu vaccines (e.g., Moderna, Pfizer/BioNTech mRNA candidates). In the antibody space, AstraZeneca's long-acting antibody (LAAB) combination for COVID-19 (Evusheld) demonstrated the prophylactic model, but it faced challenges with viral escape. For influenza, few monoclonal antibodies are in late-stage development for prophylaxis, leaving a potential niche for RQ Bio if it can demonstrate superior breadth and durability.